These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20944158)

  • 1. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.
    Coosemans A; Wölfl M; Berneman ZN; Van Tendeloo V; Vergote I; Amant F; Van Gool SW
    Anticancer Res; 2010 Sep; 30(9):3709-14. PubMed ID: 20944158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
    Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
    Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.
    Coosemans A; Vanderstraeten A; Tuyaerts S; Verschuere T; Moerman P; Berneman ZN; Vergote I; Amant F; VAN Gool SW
    Anticancer Res; 2013 Dec; 33(12):5495-500. PubMed ID: 24324087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1 peptide vaccine for the treatment of cancer.
    Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H
    Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
    Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
    Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.
    Coosemans A; Vanderstraeten A; Tuyaerts S; Verschuere T; Moerman P; Berneman Z; Vergote I; Amant F; Van Gool SW
    Anticancer Res; 2013 Sep; 33(9):3855-9. PubMed ID: 24023319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.
    Fujiki F; Oka Y; Kawakatsu M; Tsuboi A; Tanaka-Harada Y; Hosen N; Nishida S; Shirakata T; Nakajima H; Tatsumi N; Hashimoto N; Taguchi T; Ueda S; Nonomura N; Takeda Y; Ito T; Myoui A; Izumoto S; Maruno M; Yoshimine T; Noguchi S; Okuyama A; Kawase I; Oji Y; Sugiyama H
    Anticancer Res; 2010 Jun; 30(6):2247-54. PubMed ID: 20651376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
    Coosemans A; Moerman P; Verbist G; Maes W; Neven P; Vergote I; Van Gool SW; Amant F
    Gynecol Oncol; 2008 Dec; 111(3):502-8. PubMed ID: 18929401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [WT1 peptide-based immunotherapy].
    Sugiyama H
    Nihon Rinsho; 2005 Jun; 63(6):1101-9. PubMed ID: 15948398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WT1 peptide immunotherapy for cancer in children and young adults.
    Hashii Y; Sato E; Ohta H; Oka Y; Sugiyama H; Ozono K
    Pediatr Blood Cancer; 2010 Aug; 55(2):352-5. PubMed ID: 20582983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report.
    Ohta H; Hashii Y; Yoneda A; Takizawa S; Kusuki S; Tokimasa S; Fukuzawa M; Tsuboi A; Murao A; Oka Y; Oji Y; Aozasa K; Nakatsuka S; Sugiyama H; Ozono K
    Pediatr Hematol Oncol; 2009 Jan; 26(1):74-83. PubMed ID: 19206012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
    Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
    Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
    Morita S; Oka Y; Tsuboi A; Kawakami M; Maruno M; Izumoto S; Osaki T; Taguchi T; Ueda T; Myoui A; Nishida S; Shirakata T; Ohno S; Oji Y; Aozasa K; Hatazawa J; Udaka K; Yoshikawa H; Yoshimine T; Noguchi S; Kawase I; Nakatsuka S; Sugiyama H; Sakamoto J
    Jpn J Clin Oncol; 2006 Apr; 36(4):231-6. PubMed ID: 16611662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.
    Ohno S; Takano F; Ohta Y; Kyo S; Myojo S; Dohi S; Sugiyama H; Ohta T; Inoue M
    Anticancer Res; 2011 Jul; 31(7):2447-52. PubMed ID: 21873158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
    Sugiyama H
    Expert Rev Vaccines; 2005 Aug; 4(4):503-12. PubMed ID: 16117707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.